NHS, endometriosis and Ryeqo

Relugolix-estradiol-norethisterone (also known as relugolix combination therapy or Ryeqo), is the “first of its kind” daily ...
The new tablet, known as Ryeqo or relugolix-estradiol-norethisterone, has been approved to treat women of reproductive age ...
The new pill is the first long-term daily pill licensed to treat the condition, and works by blocking specific hormones that ...
This marks the first long-term, daily oral treatment for the condition, offering a significant advancement in endometriosis management. Ryeqo works by blocking hormones that contribute to ...
A FIRST-of-its-kind pill designed to transform treatment of agonising endometriosis will be available on the NHS. The condition affects an estimated 1.5 million women in the UK, causing intense ...